<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35012534</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>Monocarboxylate transporter functions and neuroprotective effects of valproic acid in experimental models of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2</StartPage><MedlinePgn>2</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12929-022-00785-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a devasting neurodegenerative disorder for which no successful therapeutics are available. Valproic acid (VPA), a monocarboxylate derivative, is a known antiepileptic drug and a histone deacetylase inhibitor.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To investigate whether monocarboxylate transporter 1 (MCT1) and sodium-coupled MCT1 (SMCT1) are altered in ALS cell and mouse models, a cellular uptake study, quantitative real time polymerase chain reaction and western blot parameters were used. Similarly, whether VPA provides a neuroprotective effect in the wild-type (WT; hSOD1WT) and ALS mutant-type (MT; hSOD1G93A) NSC-34 motor neuron-like cell lines was determined through the cell viability assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">[<sup>3</sup>H]VPA uptake was dependent on time, pH, sodium and concentration, and the uptake rate was significantly lower in the MT cell line than the WT cell line. Interestingly, two VPA transport systems were expressed, and the VPA uptake was modulated by SMCT substrates/inhibitors in both cell lines. Furthermore, MCT1 and SMCT1 expression was significantly lower in motor neurons of ALS (G93A) model mice than in those of WT mice. Notably, VPA ameliorated glutamate- and hydrogen peroxide-induced neurotoxicity in both the WT and MT ALS cell lines.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Together, the current findings demonstrate that VPA exhibits a neuroprotective effect regardless of the dysfunction of an MCT in ALS, which could help develop useful therapeutic strategies for ALS.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gyawali</LastName><ForeName>Asmita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Drug Information Research Institute, Sookmyung Women's University, Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latif</LastName><ForeName>Sana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Drug Information Research Institute, Sookmyung Women's University, Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Seung-Hye</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Korea Institute of Science and Technology, Seoul, 02792, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyeon</LastName><ForeName>Seung Jae</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Korea Institute of Science and Technology, Seoul, 02792, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Hoon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Brain Science Institute, Korea Institute of Science and Technology, Seoul, 02792, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Young-Sook</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Drug Information Research Institute, Sookmyung Women's University, Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Republic of Korea. yskang@sm.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2019R1F1A1044048</GrantID><Agency>National Research Foundation of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027501">Monocarboxylic Acid Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C507459">Slc5a8 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027981">Symporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C421223">monocarboxylate transport protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027501" MajorTopicYN="N">Monocarboxylic Acid Transporters</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="Y">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027981" MajorTopicYN="N">Symporters</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Monocarboxylate transporter 1</Keyword><Keyword MajorTopicYN="N">Neuroprotection</Keyword><Keyword MajorTopicYN="N">Sodium-coupled monocarboxylate transporter</Keyword><Keyword MajorTopicYN="N">Valproic acid</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35012534</ArticleId><ArticleId IdType="pmc">PMC8744235</ArticleId><ArticleId IdType="doi">10.1186/s12929-022-00785-3</ArticleId><ArticleId IdType="pii">10.1186/s12929-022-00785-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tefera TW, Borges K. Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments. Front Neurosci. 2017;10:611. doi: 10.3389/fnins.2016.00611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00611</ArticleId><ArticleId IdType="pmc">PMC5222822</ArticleId><ArticleId IdType="pubmed">28119559</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014;37:433&#x2013;442. doi: 10.1016/j.tins.2014.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.05.006</ArticleId><ArticleId IdType="pubmed">24927875</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48:629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyawali A, Kang YS. Transport alteration of 4-phenyl butyric acid mediated by a sodium- and proton-coupled monocarboxylic acid transporter system in ALS model cell lines (NSC-34) under inflammatory states. J Pharm Sci. 2021;110:1374&#x2013;1384. doi: 10.1016/j.xphs.2020.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.10.030</ArticleId><ArticleId IdType="pubmed">33098824</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyawali A, Kang YS. Pretreatment effect of inflammatory stimuli and characteristics of tryptophan transport on brain capillary endothelial (TR-BBB) and motor neuron like (NSC-34) cell lines. Biomedicines. 2021;9:9. doi: 10.3390/biomedicines9010009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9010009</ArticleId><ArticleId IdType="pmc">PMC7823355</ArticleId><ArticleId IdType="pubmed">33374302</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyawali A, Gautam S, Hyeon SJ, Ryu H, Kang YS. L-Citrulline level and transporter activity are altered in experimental models of amyotrophic lateral sclerosis. Mol Neurobiol. 2021;58:647&#x2013;657. doi: 10.1007/s12035-020-02143-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02143-6</ArticleId><ArticleId IdType="pubmed">33000451</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyawali A, Hyeon SJ, Ryu H, Kang YS. The alteration of L-carnitine transport and pretreatment effect under glutamate cytotoxicity on motor neuron-like NSC-34 lines. Pharmaceutics. 2021;13:551. doi: 10.3390/pharmaceutics13040551.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13040551</ArticleId><ArticleId IdType="pmc">PMC8070968</ArticleId><ArticleId IdType="pubmed">33919926</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijay N, Morris M. Role of monocarboxylate transporters in drug delivery to the brain. Curr Pharm Des. 2014;20:1487&#x2013;1498. doi: 10.2174/13816128113199990462.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/13816128113199990462</ArticleId><ArticleId IdType="pmc">PMC4084603</ArticleId><ArticleId IdType="pubmed">23789956</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RS, Morris ME. Monocarboxylate transporters: therapeutic targets and prognostic factors in disease. Clin Pharmacol Ther. 2016;100:454&#x2013;463. doi: 10.1002/cpt.418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.418</ArticleId><ArticleId IdType="pmc">PMC5533588</ArticleId><ArticleId IdType="pubmed">27351344</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuri T, Kono Y, Fujita T. Transport characteristics of 5-aminosalicylic acid into colonic epithelium: Involvement of sodium-coupled monocarboxylate transporter SMCT1-mediated transport system. Biochem Biophys Res Commun. 2020;524:561&#x2013;566. doi: 10.1016/j.bbrc.2020.01.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.01.139</ArticleId><ArticleId IdType="pubmed">32014250</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisel P, Schaeffeler E, Schwab M. Clinical and functional relevance of the monocarboxylate transporter family in disease pathophysiology and drug therapy. Clin Transl Sci. 2018;11:352&#x2013;364. doi: 10.1111/cts.12551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12551</ArticleId><ArticleId IdType="pmc">PMC6039204</ArticleId><ArticleId IdType="pubmed">29660777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui D, Morris ME. The drug of abuse &#x3b3;-hydroxybutyrate is a substrate for sodium-coupled monocarboxylate transporter (SMCT) 1 (SLC5A8): characterization of SMCT-mediated uptake and inhibition. Drug Metab Dispos. 2009;37:1404&#x2013;1410. doi: 10.1124/dmd.109.027169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.109.027169</ArticleId><ArticleId IdType="pmc">PMC2698941</ArticleId><ArticleId IdType="pubmed">19389857</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison BM, Tsingalia A, Vidensky S, Lee Y, Jin L, Farah MH, et al. Deficiency in monocarboxylate transporter 1 (MCT1) in mice delays regeneration of peripheral nerves following sciatic nerve crush. Exp Neurol. 2015;263:325&#x2013;338. doi: 10.1016/j.expneurol.2014.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.10.018</ArticleId><ArticleId IdType="pmc">PMC4292924</ArticleId><ArticleId IdType="pubmed">25447940</ArticleId></ArticleIdList></Reference><Reference><Citation>Diederich M, Chateauvieux S, Morceau F, Dicato M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010;2010:479364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2926634</ArticleId><ArticleId IdType="pubmed">20798865</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;scher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16:669&#x2013;694. doi: 10.2165/00023210-200216100-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00023210-200216100-00003</ArticleId><ArticleId IdType="pubmed">12269861</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu T, Zhou H, Lu L, Kong X, Wang T, Pan B, et al. Valproic acid-mediated neuroprotection and neurogenesis after spinal cord injury: from mechanism to clinical potential. Regen Med. 2015;10:193&#x2013;209. doi: 10.2217/rme.14.86.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/rme.14.86</ArticleId><ArticleId IdType="pubmed">25485637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Maeng S, Kang SR, Choi HY, Oh TH, Ju BG, et al. Valproic acid protects motor neuron death by inhibiting oxidative stress and endoplasmic reticulum stress-mediated cytochrome c release after spinal cord injury. J Neurotrauma. 2014;31:582&#x2013;594. doi: 10.1089/neu.2013.3146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2013.3146</ArticleId><ArticleId IdType="pmc">PMC3949506</ArticleId><ArticleId IdType="pubmed">24294888</ArticleId></ArticleIdList></Reference><Reference><Citation>Naga&#x144;ska E, Matyja E, Taraszewska A, Rafa&#x142;owska J. Protective effect of valproic acid on cultured motor neurons under glutamate excitotoxic conditions. Ultrastructural study Folia. Neuropathol. 2015;53:309&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">26785365</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Feng H, Zhang J, Jiang H. Lithium and valproate acid protect NSC34 cells from H2O2-induced oxidative stress and upregulate expressions of SIRT3 and CARM1. Neuroendocrinol Lett. 2013;34:648&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">24464007</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung MK, Kim KY, Lee NY, Kang YS, Hwang YJ, Kim Y, et al. Expression of taurine transporter (TauT) is modulated by heat shock factor 1 (HSF1) in motor neurons of ALS. Mol Neurobiol. 2013;47:699&#x2013;710. doi: 10.1007/s12035-012-8371-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8371-9</ArticleId><ArticleId IdType="pmc">PMC8383465</ArticleId><ArticleId IdType="pubmed">23180277</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyawali A, Kang YS. Blood-to-retina transport of imperatorin involves the carrier-mediated transporter system at the inner blood-retinal barrier. J Pharm Sci. 2019;108:1619&#x2013;1626. doi: 10.1016/j.xphs.2018.11.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2018.11.040</ArticleId><ArticleId IdType="pubmed">30528198</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya RS, Zhu H, Li W, Bowser R, Friedlander RM, Wang X. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci. 2013;70:4729&#x2013;4745. doi: 10.1007/s00018-013-1415-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1415-0</ArticleId><ArticleId IdType="pmc">PMC4172456</ArticleId><ArticleId IdType="pubmed">23864030</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta Mol Basis Dis. 2006;1762:1068&#x2013;1082. doi: 10.1016/j.bbadis.2006.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.05.002</ArticleId><ArticleId IdType="pubmed">16806844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ushigome F, Takanaga H, Matsuo H, Tsukimori K, Nakano H, Ohtani H, et al. Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo) Eur J Pharmacol. 2001;417:169&#x2013;176. doi: 10.1016/S0014-2999(01)00912-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(01)00912-8</ArticleId><ArticleId IdType="pubmed">11334847</ArticleId></ArticleIdList></Reference><Reference><Citation>Terbach N, Shah R, Kelemen R, Klein PS, Gordienko D, Brown NA, et al. Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid using the simple biomedical model Dictyostelium. J Cell Sci. 2011;124:2267&#x2013;2276. doi: 10.1242/jcs.084285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.084285</ArticleId><ArticleId IdType="pmc">PMC3113673</ArticleId><ArticleId IdType="pubmed">21652627</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W, Praetor K, Metzner L, Neubert RHH, Brandsch M. Transport of valproate at intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells: mechanism and substrate specificity. Eur J Pharm Biopharm. 2008;70:486&#x2013;492. doi: 10.1016/j.ejpb.2008.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2008.05.022</ArticleId><ArticleId IdType="pubmed">18577448</ArticleId></ArticleIdList></Reference><Reference><Citation>Halestrap AP. Monocarboxylic acid transport. Compr Physiol. 2013;3:1611&#x2013;1643. doi: 10.1002/cphy.c130008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.c130008</ArticleId><ArticleId IdType="pubmed">24265240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathy V, Thangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S, et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10:193&#x2013;199. doi: 10.1208/s12248-008-9022-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-008-9022-y</ArticleId><ArticleId IdType="pmc">PMC2751467</ArticleId><ArticleId IdType="pubmed">18446519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro Y, Furugen A, Narumi K, Nishimura A, Hirano T, Kobayashi M, et al. Valproic acid transport in the choriocarcinoma placenta cell line JEG-3 proceeds independently of the proton-dependent transporters MCT1 and MCT4. Drug Metab Pharmacokinet. 2018;33:270&#x2013;274. doi: 10.1016/j.dmpk.2018.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dmpk.2018.03.004</ArticleId><ArticleId IdType="pubmed">30341000</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Jiang L. Organic anion transporting polypeptide 2 transports valproic acid in rat brain microvascular endothelial cells. Neurol Res. 2016;38:634&#x2013;639. doi: 10.1080/01616412.2016.1173324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01616412.2016.1173324</ArticleId><ArticleId IdType="pubmed">27156567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno N, Takahashi T, Iwase Y, Kusuhara H, Niwa T, Sugiyama Y. Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab Dispos. 2007;35:1429&#x2013;1434. doi: 10.1124/dmd.106.013912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.106.013912</ArticleId><ArticleId IdType="pubmed">17502342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487:443&#x2013;448. doi: 10.1038/nature11314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11314</ArticleId><ArticleId IdType="pmc">PMC3408792</ArticleId><ArticleId IdType="pubmed">22801498</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Escuredo J, Van H&#xe9;e VF, Sboarina M, Falces J, Payen VL, Pellerin L, et al. Monocarboxylate transporters in the brain and in cancer. Biochim Biophys Acta Mol Cell Res. 2016;1863:2481&#x2013;2497. doi: 10.1016/j.bbamcr.2016.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2016.03.013</ArticleId><ArticleId IdType="pmc">PMC4990061</ArticleId><ArticleId IdType="pubmed">26993058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayka&#xe7; A, &#x15e;ehirli A&#xd6;. The role of the SLC transporters protein in the neurodegenerative disorders. Clin Psychopharmacol Neurosci. 2020;18:174&#x2013;187. doi: 10.9758/cpn.2020.18.2.174.</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2020.18.2.174</ArticleId><ArticleId IdType="pmc">PMC7236796</ArticleId><ArticleId IdType="pubmed">32329299</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti B, Polazzi E, Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol. 2009;2:95&#x2013;109. doi: 10.2174/1874467210902010095.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874467210902010095</ArticleId><ArticleId IdType="pubmed">20021450</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang HZ, Wang SY, Yin X, Jiang HQ, Wang XD, Wang J, et al. Downregulation of Homer1b/c in SOD1 G93A models of ALS: a novel mechanism of neuroprotective effect of lithium and valproic acid. Int J Mol Sci. 2016;17:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5187929</ArticleId><ArticleId IdType="pubmed">27999308</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>